F-1: Shenni Holdings Files for US IPO, Aiming to Raise Up to $18 Million

Shenni Holdings, a Cayman Islands-based company with operations in China, is seeking to list on the Nasdaq Capital Market through an initial public offering of 3,000,000 ordinary shares, with an expected price range of $4 to $6 per share.

Summary

• Shenni Holdings Limited, a Cayman Islands holding company, has filed a registration statement for an initial public offering (IPO) in the United States.
• The company plans to offer 3,000,000 ordinary shares with an anticipated initial public offering price between $4 and $6 per share.
• Shenni Holdings intends to list its ordinary shares on the Nasdaq Capital Market under the ticker symbol SNI.
• The offering is being made on a firm commitment basis by D. Boral Capital.
• Upon completion of the offering, Mr. Minghai Zhou, the Chairman of the board, will beneficially own a controlling stake in the company.
• Shenni Holdings operates primarily through its subsidiaries in China, focusing on the manufacture and distribution of urology medical devices and care products, as well as the distribution of cardiovascular and cerebrovascular medical devices.
• The company's revenue for the fiscal year ended March 31, 2024, was approximately $10.58 million, a significant increase from $0.62 million in the previous fiscal year.
• Net income for the same period was approximately $1.54 million, compared to a net loss of $0.12 million in the prior year.
• The company intends to use the net proceeds from the IPO for new product development, expansion of production facilities, marketing and promotion, and working capital.
• The company faces risks associated with operating in China, including regulatory uncertainties and potential government intervention.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue and income growth, but also highlights significant risks associated with operating in China and the company's reliance on a few key customers and suppliers. The sentiment is cautiously optimistic.

Positives

• The company experienced significant revenue growth in the fiscal year ended March 31, 2024, reaching $10.58 million.
• The company achieved net income of $1.54 million in the fiscal year ended March 31, 2024, a substantial improvement from the previous year's net loss.
• The company has a team of professionals specializing in medical device research and development, production, quality control, marketing, sales and distribution.
• The company's auditor is headquartered in Singapore and is subject to PCAOB inspections.
• The company has a diversified product portfolio including urology medical devices and care products as well as cardiovascular and cerebrovascular medical devices.

Negatives

• The company is a holding company with no material operations of its own, relying on subsidiaries in China.
• The company is subject to regulatory risks associated with operating in China, including potential government intervention and changes in laws and regulations.
• The company is subject to filing procedures with the CSRC in connection with the public offering.
• The company relies on a limited number of vendors, and the loss of one of our significant vendors could harm our business, and the loss of any one of such vendors could have a material adverse effect on our business.
• The company has a substantial customer concentration, with a limited number of customers accounting for a large portion of our revenues.

Risks

• Changes in China's economic, political, or social conditions could adversely affect the company's business.
• The company may face difficulties in transferring cash between the holding company and its subsidiaries due to governmental control of currency conversion.
• The Holding Foreign Companies Accountable Act and related regulations could pose regulatory risks and impose restrictions on the company.
• The company may be unable to bring an action against the company or its officers and directors or to enforce any judgment you may obtain.
• The company may be subject to product liability claims, and we do not have insurance coverage to cover these claims.
• The company faces growing competition in urology medical devices and care products market as well as the cardiovascular and cerebrovascular medical devices market in China.

Future Outlook

The company aims to bring smarter, efficient, and accessible and minimally invasive surgical instruments to doctors and patients in China and plans to develop a total of 20 new products in the next 2-3 years.

Industry Context

The prospectus includes an industry overview based on a report by CEVSN Information Consulting Co., Ltd, providing information regarding the company's industry and market position in China.

Comparison to Industry Standards

• The document mentions competitors such as Jiangxi Langhe Medical Devices Co., Ltd., Weihai Medison Medical Devices Co., Ltd., Shanghai MicroPort Medical Devices Co., Ltd., and Shenzhen Huitai Medical Devices Co., Ltd.
• Jiangxi Langhe Medical Devices Co., Ltd.'s first product for circumcision anastomosis is recognized as a subversive surgical instrument.
• Weihai Medison Medical Devices Co., Ltd. optimized the structure of the childrens circumcision ring, simplified the surgical operation and reduced the production cost, improved the production efficiency and capacity.
• Shanghai MicroPort Medical Devices Co., Ltd. invented a new type of stent system for coronary heart disease.
• Shenzhen Huitai Medical Devices Co., Ltd. went public on the STAR Market of the Shanghai Stock Exchange in 2021 and has four major business segments: electrophysiology, coronary access, peripheral intervention, and OEM (original equipment manufacturing).

Management Changes

Related Party Transactions

• The company has engaged in transactions with related parties, including leasing property from Jiangxi Yuansheng Langhe Pharmaceutical Co., Ltd.
• The company has entered into a Medical Devices Purchase Agreement with Nanchang Mingnuo Technology Co., Ltd.

Stakeholder Impact

• Shareholders face risks related to regulatory uncertainties in China and potential government intervention.
• Employees may be affected by changes in labor laws and regulations in China.
• Customers may benefit from the company's commitment to innovation and quality control.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.

Next Steps

• The company will apply to have its Ordinary Shares listed on the Nasdaq Capital Market.
• The company will complete the remittance process to transfer the net proceeds from the Offering to China.
• The company will develop new product lines, expand the production facility, and implement marketing and promotion strategies.

Key Dates

Keywords

IPO, Shenni Holdings, medical devices, urology, cardiovascular, cerebrovascular, China, Nasdaq, offering, healthcare